AstraZeneca Announces $3.5 Bn Investment in US Expansion
This expansion aligns with AstraZeneca’s broader strategy to achieve $80 billion in total revenue by 2030, as outlined in May.
Pharma giant AstraZeneca has planned to invest $3.5 billion in the United States by the end of 2026, aiming to enhance its research and manufacturing capabilities. The initiative includes $2 billion in new capital, projected to create over 1,000 high-skilled jobs.
The investment will bolster AstraZeneca's footprint in the US, its largest market, accounting for 44% of its total revenue.
Key developments include:
An R&D center in Kendall Square, Cambridge, Massachusetts.
A biologics manufacturing facility in Maryland.
Cell therapy manufacturing on the West and East Coasts.
Specialty manufacturing capabilities in Texas.
This expansion aligns with AstraZeneca’s broader strategy to achieve $80 billion in total revenue by 2030, as outlined in May.
The US market plays a central role in this plan, reflecting the company's focus on accelerating its growth in the region.
AstraZeneca's investments mark a significant step in advancing its research and production capabilities while contributing to local job creation and economic growth.
